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Abstract
BRIC nations – Brazil, Russia, India, and China – represent 40% of the world’s population, including a growing 
aging population and middle class with an increasing prevalence of chronic disease. Their healthcare systems 
increasingly rely on prescription drugs, but they differ from most other healthcare systems because healthcare 
expenditures in BRIC nations have exhibited the highest revenue growth rates for pharmaceutical multinational 
corporations (MNCs), Big Pharma. The response of BRIC nations to Big Pharma presents contrasting cases 
of how governments manage the tensions posed by rising public expectations and limited resources to satisfy 
them. Understanding these tensions represents an emerging area of research and an important challenge for all 
those who work in the field of health policy and management (HPAM).
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BRIC nations – Brazil, Russia, India, and China – represent 40% of the world’s population, including a growing aging population and middle class with an 
increasing prevalence of chronic disease.1 As in healthcare 
systems among G7 nations, they rely increasingly on 
prescription drugs, but they differ from these mature nations 
with respect to healthcare expenditure growth. Although 
BRIC nations spend far less than the average of G7 nations 
on healthcare, as a percent of gross domestic product (GDP), 
and accounted for a much smaller share of the global market 
in 1995 (9% in $PPP [purchasing power parity]), since then 
this share has almost doubled (16% in 2012).2 BRIC nations’ 
healthcare expenditure growth rates, between 1995-2013, 
exceeded those of G7 nations whose percentage share of global 
health spending fell, mostly due to the growth of healthcare 
expenditure in BRIC nations.2 Likewise, pharmaceutical 
multinational corporations (MNCs), henceforth Big Pharma, 
have seen their highest revenue growth in BRIC nations 
whose markets they refer to as “pharmerging.”3 Since 2012, 
IMS Health estimates Big Pharma’s compound average 
annual revenue growth rates at 13% in comparison to 2% in 
the top eight mature markets.3 During this same period, IMS 
estimates a 17% compound annual growth rate, in China, and 
an average of 12% for Brazil, Russia, and India.3 
Big Pharma has always sought to maximize its sales of 
branded drugs and protect its intellectual property rights. 
Since the AIDS crisis, however, Brazil and India turned to 
compulsory licensing to make life saving drugs available to 
their populations. Also, Big Pharma had to contend with 
patent expiration for half of the world’s 100 best selling 
medicines.4 In addition, in mature markets, the growth of less 
expensive generic drugs and the strengthening of regulations 
governing the efficacy and safety of new medicines led Big 
Pharma to introduce new strategies to maintain its profit 
margins and global revenue growth rates.5 The so-called 
patent cliff exacerbated Big Pharma’s traditional business 
model of spending more on marketing and promotion of 
“me-too medicines” than on research and development.4,6-9 In 
the context of higher sales revenue growth in BRIC nations, 
Big Pharma has adapted their business models to these 
pharmerging markets. 
BRIC nations present a number of risks to Big Pharma. They 
all have less well developed healthcare systems, a shortage of 
expertise in some domains, a history of problems with quality 
control, economic crisis, and corruption.5 On the other hand, 
they may make it possible to lower the costs of clinical trials 
and other aspects of drug development. Moreover, periods 
of prosperity in BRIC nations, and aging middle-class 
populations, have led to rapidly changing disease patterns.1 Of 
course, there are striking differences among BRIC nations with 
respect to population health,1 the financing and organization 
of health services, and healthcare coverage.10 Their response 
to Big Pharma presents contrasting examples of the tensions 
posed by rising public expectations and limited resources 
to satisfy them. Understanding these tensions represents an 
emerging area of important research and a challenge for all 
those who work in the field of health policy and management 
(HPAM).
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Population Health and Healthcare Systems
Beyond the problems of HIV/AIDS and tuberculosis (TB), 
which challenged Big Pharma’s intellectual property regime, 
BRIC nations now confront the rise of non-communicable 
disease (NCD) associated with rising urbanization and 
pollution, especially in China and India (Table 1). Russia lags 
behind Brazil and China with respect to life expectancy at birth 
and mortality from NCD (Table 1). India still lags far behind 
Brazil, China, and Russia with respect to life expectancy at 
birth, which reflects its significantly higher mortality from 
communicable disease. As for NCD, India’s death rates are 
higher than Brazil and China, but lower than Russia.
BRIC nations’ contrasting models of healthcare financing 
and organization reflect political and institutional features 
that are important to understanding their response to Big 
Pharma. Russia, although the wealthiest, among BRIC 
nations, measured by GDP per capita, in PPP prices, spends 
significantly less on healthcare (6.1% of GDP) than Brazil 
(8.3%) (Table 2). China, third in GDP per capita, spends 
only 5.6% of its GDP on healthcare, while India spends only 
4.8%. Most striking is the relative share of public and private 
expenditure on healthcare. India’s public share of healthcare 
expenditure is only 29% (1.4% of GDP) in contrast to 55% 
in China (3.1% of GDP), 60% in Russia (3.7% of GDP) and 
46% in Brazil (3.8% of GDP). Likewise, India is the outlier 
with respect to out-of-pocket (OOP) payment by patients, 
as a share of total healthcare expenditures: 65.6% in India 
in contrast to 25.5% in Brazil, 45.8% in Russia and 34.6% in 
China (Table 2).11
Market Access for Big Pharma
Big Pharma’s largest and fastest growing market is obviously 
in China due to its size and economic growth.12 China’s 
annual growth in per capita healthcare expenditure over 
the period 1995-2012 was 10.4% in comparison to Brazil’s 
(3.3%), India’s (6.4%) and Russia’s (5.4%).11 Although Brazil, 
India, and Russia currently have similar sized pharmaceutical 
markets, India stands out as the nation with the lowest per 
capita pharmaceutical expenditures (Table 3).13 In terms of 
Big Pharma’s presence within each nation, and the extent to 
which the population has access to patented drugs, Brazil 
stands out as the nation with the highest share of its total 
expenditure on these medicines (47%), in contrast to China 
(22%), Russia (21%), and India (9.3%).14
Table 1. Population Health and NCD: Indicators in BRIC Nations, 2012-2017
Indicator Brazil Russian Federation India China
Population (millions)a 205.9 143.8 1309 1397
Life expectancy at birthb 75.2 70.9 68.3 76.1
Age standardized mortality rate from NCD per 100 000c 450 716 600 550
Cancer mortality per 100 000 populationd 103.7 122.6 64.5 122.2
Probability of dying  (ages of 30-70) from CVD, cancer, diabetes, chronic respiratory disease (%) c 17 29 23 18
Abbreviations: NCD, non-communicable disease; CVD, Cardiovascular disease; BRIC, Brazil, Russia, India, and China.
Sources: a United Nations Population Division (2017). World Population Prospects.
b World Bank (2015).
c WHO. Global Health Observatory Data Repository (2015).
d Cancer Research UK – Worldwide Cancer Mortality Statistics (2012).
Table 2. Healthcare Expenditure in BRIC Nations, 2014-2016 
 Brazil Russian Federation  India China
GDP per capita in PPPa 16 096 24 805 5855 12 880
GNI per capitab 14 810 22 540 6490 15 500
Human development indexc 0.754 0.804 0.624 0.738
Gini indexd 51.3 37.7 35.2 42.2
Public expenditure on health (% of GDP)e 3.8 3.7 1.4 3.1
Private expenditure on health (% of GDP)e 4.5 2.4 3.4 2.5
Total expenditure on health (% of GDP)e 8.3 6.1 4.8 5.6
OOP health expenditure (% of private health expenditure)e 47.2 88 95.9 72.3
OOP health expenditure (% of total healthcare expenditure)e 25.5 45.8 65.6 34.6
OOP health expenditure per capita in PPPf $343 $506 $90 $165
Abbreviations: OOP, Out-of-pocket; PPP, purchasing power parity; GDP, gross domestic product; BRIC, Brazil, Russia, India, and China; GNI, Gross national 
income.
a World Economic Outlook Database, International Monetary Fund (2014).
b The World Bank (2016). 
c HDI is a composite statistic (composite index) of life expectancy, education, and per capita income indicators, Human Development Report UNDP. (2015)
d GINI index of 0 represents perfect equality while an index of 100 implies perfect inequality. World Bank. (Brazil and Russia-2015 China-2012 India-2011) 
e The World Bank (2014).
f Reference 11.
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With respect to their capacity to assure domestic production 
of pharmaceuticals, both generic and branded generics, Russia 
is the most dependent on imported medicines, as a share of 
its total pharmaceutical sales (57.8%), in contrast to Brazil 
(34.7%), China (17.9%), and India (9.7%). These differences, 
among BRIC nations, reflect many factors, including the size 
of their markets for pharmaceuticals, their industrial policies 
with respect to domestic production of pharmaceuticals, the 
terms on which they have negotiated Big Pharma’s market 
access, and the extent to which they provide their populations 
with publicly financed healthcare and prescription drug 
coverage.5,15,16
Brazil 
Since 1988, when Brazil’s constitution established a right to 
healthcare, and two years later adopted the Unified Health 
System (Sistema Unico de Saude - SUS), the Ministry of Health 
led a campaign to provide universal health coverage (UHC), 
backed up by strong federal, state and local government 
support to implement the policy. Since 2002, consistent with 
this goal, Brazil’s Farmacia Popular provides prescription 
drug coverage, based on a national list of essential drugs, for 
all patients suffering from hypertension, diabetes, asthma 
and a number of other conditions.17 Medications have also 
included imports, and more recently, under the banner of 
judicialization, the poor, as well as middle class patients have 
taken legal measures to assure access to a high volume of 
medicines that few nations now supply to their population.18
Brazil has also been a leader in the use of compulsory licensing 
to promote access to essential medicines, especially with 
respect to HIV/AIDS. By volume, domestic companies hold 
around 70% of the pharmaceutical market.19 With respect to 
revenue, however, Big Pharma now controls about one-half of 
the market. This figure underestimates its presence as MNCs 
have been active in mergers and acquisitions of domestic 
companies. 
In the present context of economic recession, the government 
is attempting to impose spending controls through 
centralization of purchases and strengthening regulation 
of pharmaceutical prices, eg, ANVISA’s (Agência Nacional 
de Vigilância Sanitária) denials to provide some high cost 
prescription drugs not included in its guidelines.20 This may 
well reduce the growth of publicly financed pharmaceutical 
expenditures, but Brazil’s population appears in a stronger 
position to demand these benefits than their counterparts in 
Russia, India, and China.
Russia 
As in Brazil, Russians have a constitutional right, in principle, 
to free healthcare and every citizen is assigned to a polyclinic 
based on their place of residence. In practice, however, 
outpatient prescription drugs are excluded from coverage for 
most of the population, which results in high OOP payments. 
The Vital Drug List includes essential drugs covering mostly 
seniors, the disabled, children and pregnant women. The 
largest share of these medicines is imported from abroad 
and are free, in principle, in hospitals. However, this sector 
represents only about 20 percent of all prescription drugs 
sold.21 The generic drug market accounted for over 80% of the 
pharmaceutical market in volume (and almost 50% in value) 
in 2006. The gap between the volume and value of this market 
indicates a pricing problem because relatively high prices are 
paid to manufacturers who are not known for developing new 
molecules.21
In the context of international sanctions, and strong reliance 
by Russia on pharmaceutical imports, the government 
announced an import substitution strategy to ensure that local 
drug production covers one-half of generic drugs by 2017, and 
half of all innovative drugs by 2020.22 Nonetheless, Russia’s 
pharmaceutical sector today is conspicuous for its continued 
reliance on imports and the relative underdevelopment of 
domestic production. Pharmaceuticals produced by Big 
Pharma rank at the top of all imports to Russia.23 Measured 
in US dollars, due to the sanctions and devaluation of the 
Rouble, domestic consumption of pharmaceuticals sold by 
Big Pharma has decreased. In 2015, in contrast to its BRIC 
counterparts, the volume of pharmaceutical “packets” on 
Russia’s retail market declined to their levels in 2006.24 
India 
In contrast to the government’s weak involvement in India’s 
healthcare system, with regard to the pharmaceutical sector, 
the Indian government has promoted a strong manufacturing 
sector following the Indian Patent Act of 1970, which denied 
product patents and recognized only process patents. This 
made it possible for domestic manufacturers to develop a 
competitive pharmaceutical sector with far lower production 
costs than those of Big Pharma, and eventually to serve as the 
Table 3. BRIC Pharmaceutical Market, 2016
 Brazil Russian Federation India China
Pharmaceutical sales (in US$ Billion)a 18.38 15.4 17.45 116
Per capita (in  US$)a 88 107 13 8.3
Pharmaceutical value imported (in US$ Billion)b 6.39 8.9 1.69 20.77
% Imported pharmaceutical salesa 34.76 57.79 9.68 17.9
% Expenditure on patented drugsa 47 21 9.3 22
Pharmaceutical spend as % of total health expenditure (2009)c 25.1 20.3 40.9 42.5
Abbreviation: BRIC, Brazil, Russia, India, and China.
Sources:
a International Trade Administration. 2016 Top Markets Report – Pharmaceuticals.
b ITC. Calculations based on UN COMTRADE statistics.
c Reference 13.
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world’s factory for generic medicines. In terms of volume, 
India’s pharmaceutical sector for generic prescription drugs 
accounts for 20% of global export volume25 and 40% of all 
generic and over-the-counter pharmaceuticals sold in the 
United States.26 
Big Pharma has challenged India’s Supreme Court and 
Intellectual Property Appellate Board for their failure to 
grant more patents and for issuing compulsory licenses.27 
However, India continues to limit the influence of Big 
Pharma and instead promotes its own manufacturers of 
generic medicines. One might presume that such policies 
would reduce pharmaceutical prices and thereby improve 
access to drugs for Indian patients. However, despite the 
low production costs, domestic companies often sell their 
generics with sales margins often as high as 1000% to 4000% 
of their costs.28,29 Although the government had announced 
free access to medicines in public health facilities as a goal in 
2012, this objective was abandoned in 2015.30 
As one of the most privatized healthcare systems, 
worldwide, in 2013 the government authorized the National 
Pharmaceutical Pricing Authority to regulate the prices of 
530 essential medicines.31 However, many Indian physicians 
prescribe branded generic drugs without concern for higher 
prices, or simply because they do not trust the quality of 
generics. Consequently, Indian patients devote 60% to 90% 
of their OOP healthcare spending to medicines whose costs 
have become a leading cause of impoverishment.32
China 
In 2009, China enacted an ambitious health reform aimed at 
increasing public health financing, providing essential drugs, 
expanding primary health facilities, and achieving UHC by 
2020.33 The government’s recent investments in healthcare are 
part of a shift from export-led growth strategies to inclusive 
development strategies within the domestic market.34 Most 
new expenditures have subsidized urban and rural residents 
not already covered by the principal health insurance funds. 
In addition, in contrast to India, the government paid primary 
healthcare providers to deliver a minimum defined package of 
public health services and established the Essential Medicines 
Program.35
China’s domestic market is highly fragmented among 
over 5000 domestic manufacturers that export active 
pharmaceutical ingredients (APIs). Their production of 
final products, mostly generic medicines, is known for their 
uneven quality. Since the life sciences are a high priority 
for research and innovation, Chinese policy has promoted 
collaboration and technology transfer among domestic firms 
and Big Pharma by providing a favorable legal environment 
(through tax incentives), liberalization of drug prices and 
excellent conditions offered to highly qualified Chinese 
citizens returning from abroad.36 Also, since China’s 
healthcare reforms have increased healthcare expenditures, 
this has strengthened the attractiveness of the second largest 
domestic pharmaceutical market in the world. As of 2012, Big 
Pharma had already captured 20% of this market with each of 
the top 10 MNCs having invested between $3 billion and $9 
billion.37
In contrast to Russia, 80% of medicines, in China, are 
distributed through public hospitals, which have until 
last year’s implementation of the zero mark-up policy, 
covered a large part of their budget through such sales.38 
Chinese health policy today seeks to reduce the prices of 
all medicines, including those of Big Pharma, through a 
tendering process both at the central and provincial levels.39 
Unfortunately, current tendering policies have created 
multiple areas of dysfunction ranging from high prices, low 
drug quality, irrational prescribing, access problems and 
discouragement of innovation due to slow and complicated 
drug approval procedures.40,41 Since 2011, as expenditures on 
pharmaceuticals have grown, price increases declined to 1% in 
2016.39 To compensate for this downward pressure on prices, 
the government has agreed to accept new drugs from MNCs 
and to accelerate the approval process for innovative drug 
products, which in the past has often taken up to 7 years.42 
Despite declines in profit margins of Big Pharma, prospects 
for continued profitability through higher sales volumes 
loom large, and as Ting Huang put it, the “dance between Big 
Pharma and the Chinese government will go on” [T. Huang 
unpublished data, 2017].
Concluding Observations
From the perspective of Big Pharma, China represents the 
greatest opportunity to develop market share and draw on 
skilled human resources and great manufacturing potential. 
There is, of course, the risk of being subject to the central 
government’s insistence on assuring technology transfer in 
exchange for market access. Russia remains an important 
market, as the nation is likely to invest heavily in healthcare 
– at least in its wealthier regions. Beyond roughly half of 
the market now held by Big Pharma, Brazil will continue 
to provide fertile ground for mergers and acquisitions of 
national companies. Also, Brazil can serve as a testing ground 
for the expression of popular demand for newly branded 
pharmaceuticals. As for India, competition on quality in 
the branded generic and newly branded pharmaceuticals 
still represents an opportunity for Big Pharma as the 
government is open to MNCs and encourages investment, 
while remaining protective of its manufacturing base for 
generic medicines. 
As we have noted, Big Pharma has developed different 
strategies to sell their medicines among the rapidly growing 
BRIC markets. Likewise, BRIC nations have responded in a 
manner that reflects their respective market size, institutions, 
negotiating power, and public health and industrial policies. 
These factors are critical in determining the potential role of 
BRIC nations as innovation hubs and the conditions affecting 
the implementation of their proclaimed policies. In the future, 
as in G7 nations, the role of government is likely to increase 
in attempting to improve access to state-of-the art medicines 
as well as the drug development process. We agree with Naci, 
Carter and Mossialos that “collective, concerted regulatory 
action is needed to send the correct signals to pharmaceutical 
companies.”9 
The field of HPAM has focused mostly on hospitals, medical 
technologies and access to primary care. But as prescription 
Rodwin et al
International Journal of Health Policy and Management, 2018, 7(3), 201–206 205
drugs have become more effective and expensive, leaders in 
the field, worldwide, would do well to pay more attention 
to medicines and the drug development process. It is not 
sufficient to analyze these issues only from the point of view of 
pharmaceutical pricing strategies and reimbursement. Health 
policy analysts will need to reflect on the gaps among relevant 
theory, policy and practice43 and focus on pharmaceutical 
policy from a broader health system perspective.44 More 
research and attention to these issues will be useful in 
developing appropriate strategies to assure that healthcare 
systems obtain the prescription drugs they need on the most 
favorable terms possible.
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